05/2021: Tcell Tolerance GmbH assigned UGA Biopharma to develop a highly efficient CHO cell line and bioprocess
UGA Biopharma is developing a new and more efficient CHO-DG44 cell line for German-based startup Tcell Tolerance GmbH to express its Palixizumab® antibody.
The new cell line will assist Tcell Tolerance in its quest to develop an innovative therapy to prevent graft-versus-host disease (GvHD), which occurs after allogeneic hematopoietic stem-cell transplantation (HSCT). Tcell Tolerance wants to develop a safer HSCT therapy that can be translated into clinical practice.
To read the full article, please click here.
ContactUGA Biopharma GmbH
Phone: +49(0)3302 / 2024900